



LINCOLN PHARMACEUTICALS LIMITED



LINCOLN
PHARMACEUTICALS LTD.
HEALTHCARE FOR ALL

Regd. Office: "LINCOLN HOUSE" Behind Satyam Complex, Science City Road, Sola, Ahmedabad-380060.

CIN: L24230GJ1995PLC024288, Ph. No.: +91-79-6777-8000, Fax: +91-79-6777-8062,

Website: www.lincolnpharma.com, E-Mail: info@lincolnpharma.com.

LINCOLN
PHARMACEUTICALS LTD.
HEALTHCARE FOR ALL

Statement of Standalone and Consolidated Un-Audited Financial Results for the Quarter and Nine-Months Ended on 31-December-2017.

PART-I		(Rs. In Lakhs)									
Sr. No.	Particulars	Standalone					Consolidated				
		Quarter Ended			Nine-Months Ended		Quarter Ended			Nine-Months Ended	
		31/12/2017 (Un-Audited)	30/09/2017 (Un-Audited)	31/12/2016 (Un-Audited)	31/12/2017 (Un-Audited)	31/12/2016 (Un-Audited)	31/12/2017 (Un-Audited)	30/09/2017 (Un-Audited)	31/12/2016 (Un-Audited)	31/12/2017 (Un-Audited)	31/12/2016 (Un-Audited)
1	Revenue from Operation	7,555.78	8,563.51	6,424.40	24,894.50	21,115.04	8,018.41	8,965.40	7,201.18	32,062.77	23,698.59
2	Other Income	273.71	290.71	316.78	820.16	992.18	283.42	299.19	326.53	866.85	1,021.52
3	Total Income from Operations (Net) (1 + 2)	7,829.49	8,854.22	6,741.18	25,714.66	22,107.22	8,301.84	9,264.58	7,527.71	32,929.62	24,720.11
4	EXPENSES										
(a)	Cost of Materials Consumed	1,687.28	1,754.84	1,331.37	4,697.15	4,202.04	2,461.24	2,413.01	1,875.65	6,684.76	5,669.05
(b)	Purchase of Stock-In-Trade	2,085.89	2,169.06	2,635.27	8,500.82	7,142.22	1,551.18	1,505.12	2,510.15	12,724.55	7,162.81
(c)	Changes in Inventories of Finished Goods, Work-In-Progress and Stock-In-Trade	-318.63	638.99	-542.93	529.28	-314.15	-424.34	638.16	-629.06	358.89	-442.66
(d)	Excise Expense	0.00	0.00	143.25	55.76	240.78	0.00	0.00	171.72	123.37	326.18
(e)	Employee Benefits Expense	1,425.37	1,263.41	1,022.15	3,739.00	3,317.48	1,513.32	1,337.78	1,082.38	3,968.47	3,582.32
(f)	Finance Cost	94.66	103.10	101.37	315.19	397.84	136.78	149.58	135.17	447.15	524.54
(g)	Depreciation and Amortisation Expense	96.50	137.02	104.00	329.52	286.33	139.43	180.69	146.00	458.12	412.33
(h)	Other Expenses	1,203.90	1,438.31	1,245.36	4,019.40	3,667.34	1,302.09	1,528.23	1,325.98	4,343.21	3,870.64
	Total Expenses (a + h)	6,274.96	7,504.74	6,039.84	22,186.13	18,939.88	6,679.71	7,752.56	6,617.99	29,108.52	21,105.21
5	Profit/(Loss) from Operations Before Exceptional Items & Tax (3 - 4)	1,554.53	1,349.49	701.34	3,528.53	3,167.34	1,622.13	1,512.02	909.72	3,821.10	3,614.90
6	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
7	Profit/(Loss) from Ordinary Activities Before Tax (5 + 6)	1,554.53	1,349.49	701.34	3,528.53	3,167.34	1,622.13	1,512.02	909.72	3,821.10	3,614.90
8	Tax Expense										
(a)	Current Tax	416.80	355.58	144.92	898.54	641.74	431.89	390.64	188.70	962.64	735.97
(b)	Deferred Tax	24.41	0.62	55.63	73.04	170.76	31.87	-10.87	64.63	76.14	197.75
9	Net Profit/(Loss) for the period (7 - 8)	1,113.32	993.29	500.79	2,556.95	2,354.84	1,158.37	1,132.25	656.39	2,782.32	2,681.18
10	Share of Profit / (loss) of associates	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
11	Minority Interest	0.00	0.00	0.00	0.00	0.00	0.64	1.90	2.21	3.19	4.61
12	Net Profit/(Loss) after taxes, minority interest and share of profit/(loss) of associates (9+10-11)	1,113.32	993.29	500.79	2,556.95	2,354.84	1,157.73	1,130.35	654.18	2,779.13	2,676.57
13	Other Comprehensive Income	-1.56	-1.55	1.42	-4.66	4.26	-1.50	-1.49	1.52	-4.48	4.56
14	Total Comprehensive Income (12 + 13)	1,111.76	991.74	502.21	2,552.29	2,359.10	1,156.23	1,128.86	655.70	2,774.65	2,681.13
15	Paid-up equity share capital of face value Rs.10/- each	2,000.00	2,000.00	2,000.00	2,000.00	2,000.00	2,000.00	2,000.00	2,000.00	2,000.00	2,000.00
16	Earnings Per Equity Share (Not Annualised)										
(a)	Basic	5.57	4.97	2.50	12.78	11.77	5.79	5.65	3.27	13.90	13.38
(b)	Diluted	5.57	4.97	2.50	12.78	11.77	5.79	5.65	3.27	13.90	13.38

NOTES:					
1	The Financial Results of the Company for the Quarter Ended December 31, 2017 have been reviewed and recommended by the Audit Committee and approved by the Board of Directors of the Company in their meeting held on January 31, 2018. The Statutory Auditors of the Company have carried out Limited Review of these Results and the Results are being Published in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.				
2	There is a possibility that these Quarter/Nine-Months Financial Results along with the Un-Audited Financial Statements as of and for the period Ended December 31, 2016 and December 31, 2017, may require adjustment before constituting the final IND-AS Financial Statements as of and for the year Ending March 31, 2018. The changes could be in Financial Reporting requirements arising from new or Revised Standards or Interpretations issued by MCA or valuation and classification changes in the use of one or more optional exemptions from full retrospective application of certain IND-AS as permitted under IND-AS-101.				
3	From the applicability of Goods and Service Tax (GST) with effect from 1 July, 2017, Revenue From Operations are disclosed Net of GST. Accordingly the Revenue From Operations and Excise Duty Expense for the Quarter and Nine-Months Ended December 31, 2017 are not comparable with the previous periods presented in the results.				
4	The Financial Results have been prepared based on the IND-AS issued and effective on the date of adoption of the results by the board. These Financial Results may require adjustment on account of any changes in the standards or subsequent clarification (if any) as issued by the MCA.				
5	The format for Un-Audited Quarterly Results as prescribed in SEBI's Circular CIR/CFD/CMD/15/2015 dated November 30, 2015 has been modified to comply with requirements of SEBI's Circular CIR/CFD/FAC/62/2016 dated July 5, 2016, IND-AS and Schedule III (Division II) to the Companies Act, 2013 applicable to Companies that are required to comply with IND-AS.				
6	The Statement does not include IND-AS compliant results for the Previous Year Ended March 31, 2017 as the same is not mandatory as per SEBI Circular CIR/CFD/FAC/62/2016 dated July 5, 2016.				
7	Consequent to transition from the previous IGAAP to IND-AS, the Reconciliation of Profit / (Loss) for the Quarter Ended December 31, 2016; Nine-Months Ended December 31, 2016 is provided below in accordance with the requirements of Paragraph 32 of IND-AS 101, "First Time Adoption of IND-AS."				
	Particulars	Standalone		Consolidated	
		Quarter Ended on December 31, 2016	Nine-Months Ended on December 31, 2016	Quarter Ended on December 31, 2016	Nine-Months Ended on December 31, 2016
	Net Profit as per IGAAP	493.63	2,284.44	647.12	2,606.47
	Add / (Less): Adjustments for GAAP Differences				
	Effect of measuring investments at fair value through Profit and Loss	0.00	0.00	0.00	0.00
	Effect of measuring Loan to Employee at Fair Value through Profit and Loss	0.97	-1.03	0.97	-1.03
	Borrowings measured at Amortised Cost & Effect on Finance Cost	-0.34	-1.83	-0.34	-1.83
	Effect of measuring Lease Liability on Leasehold Land	0.00	0.00	0.00	0.00
	Deferred and Current Tax adjustments	-4.20	-41.01	-4.20	-41.01
	Others-Effect of remeasurement of other Expense	12.15	118.53	12.15	118.53
	Net Profit after OCI as per Ind AS	502.21	2,359.10	655.70	2,681.13
8	Segment Reporting as defined in IND-AS 108 is not applicable, since the Company has only one reportable segment i.e. Pharmaceuticals.				
9	Comparative figures have been rearranged/regrouped wherever necessary.				
10	Consolidated results includes results of its subsidiaries.				
FOR LINCOLN PHARMACEUTICALS LTD.					
PLACE: AHMEDABAD DATE: JANUARY 31, 2018		Sd/- MAHENDRA G. PATEL MANAGING DIRECTOR DIN: 00104706			